The Paul-Ehrlich-Institut (PEI) is a federal institute under the German Federal Ministry of Health, dedicated to the research and evaluation of biomedicinal products, including vaccines, blood products, and advanced therapy medicinal products (ATMPs). The institute plays a crucial role in ensuring the quality, efficacy, and safety of these medical products through rigorous testing and regulatory oversight. It collaborates internationally with various organizations, including the European Medicines Agency (EMA) and the World Health Organization (WHO), to maintain high standards in the approval and monitoring processes for pharmaceuticals.

In addition to its regulatory functions, the PEI is actively involved in research and development, focusing on immunological medicines, allergenic products, and veterinary medicines. The institute emphasizes the importance of pharmacovigilance, which involves monitoring the safety of drugs post-approval, and provides training materials and guidance for pharmaceutical companies and startups. Through its commitment to scientific excellence and public health, the PEI contributes significantly to the advancement of biomedicine and the protection of global health.

Germany

Paul-Ehrlich-Institut is a healthcare regulatory agency that oversees pharmaceuticals, approves vaccines, conducts biomedical research, and protects public health.

Paul-Ehrlich-Institut

Company Details